Sutent
Keytruda/Inlyta combo scores FDA approval in advanced kidney cancer
April 23, 2019Manufacturing and Production, Sales and Marketing FDA, MSD, Pfizer, Sutent, inlyta, keytruda, pharma
MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) has secured another approval from the FDA, this time as a first-line treatment in combination …
FDA expands use of Pfizer’s Sutent in kidney cancer
November 17, 2017Medical Communications, Sales and Marketing Cancer, Kidney cancer, Pfizer, Sutent, pharma
Pfizer has announced that the FDA has expanded the use of its tyrosine kinase inhibitor Sutent (sunitinib malate) to include …
Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial
October 11, 2016Manufacturing and Production, Research and Development Cabometyx, Exelixis, Pfizer, Phase II, Sutent, advanced renal cell carcinoma
Phase II results presented by genomics-based discovery company Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …
NICE backs Pfizer’s drug for advanced kidney cancer
December 16, 2014Sales and Marketing NICE, Pfizer, Sutent, Votrient, Zytiga, axitinib, inlyta, xofigo
UK healthcare guidance body NICE has issued final draft guidance recommending Pfizer’s Inlyta for advanced kidney cancer. The draft recommendation …
Pfizer revenue drops, but new cancer drugs shine
July 29, 2014Research and Development, Sales and Marketing Cancer, Inlyta. axitinib, Lipitor, Lyrica, Pfizer, Q2, Sutent, viagra
Pfizer saw a 2% drop in sales for the second quarter but has pointed to the stellar growth of its …
‘More patients want Votrient’
April 2, 2014Research and Development, Sales and Marketing Cancer, GSK, Pfizer, Sutent, Votrient
GlaxoSmithKline is looking at patient satisfaction as a potential marketing tool for its kidney cancer drug Votrient, setting up a …
SMC approves Inlyta
November 13, 2013Sales and Marketing Pfizer, SMC, Sutent, inylta, rcc
Pfizer’s kidney cancer drug Inlyta has been approved by the drugs watchdog in Scotland, making it the only country in …
Survival boost for Votrient in mRCC
October 2, 2012Research and Development, Sales and Marketing GSK, Nexavar, Pfizer, Sutent, Votrient
GlaxoSmithKline’s renal cell carcinoma drug Votrient has proved itself non-inferior to a bitter rival, Pfizer’s Sutent, in terms of progression-free …
Torisel-Avastin combo fails in kidney cancer
August 13, 2012Research and Development, Sales and Marketing R&D, Sutent, Torisel, avastin, failure, rcc
Combining Pfizer’s Torisel and Roche’s Avastin does not increase survival rates for advanced kidney cancer patients. This is according to …
Pfizer’s Inlyta gains European recommendation
May 28, 2012Sales and Marketing Inlyta. axitinib, Sutent, renal cell carcinoma
Pfizer’s kidney cancer pill Inlyta has been recommended for use by a European committee. The Committee for Medicinal Products for …
FDA approves Pfizer cancer drug Inlyta
January 30, 2012Sales and Marketing Nexavar, Pfizer, Sutent, rcc, renal cell carcinoma
Pfizer’s kidney cancer drug Inlyta has gained US approval for second line treatment for the disease. Inlyta (axitinib) is now …
The renal cell carcinoma market: Votrient to challenge Sutent’s lead
November 25, 2010Sales and Marketing GSK, GlaxoSmithKline, Pfizer, Sutent, Votrient, rcc, renal cell carcinoma
After decades of no new medicines emerging to treat renal cell carcinoma, no fewer than five new drugs were approved …
Sutent disappoints in lung cancer
August 24, 2010Research and Development, Sales and Marketing NSCLC, Pfizer, Sutent, Tarceva
Pfizer’s Sutent has failed to improve overall survival in lung cancer patients when combined with Roche’s Tarceva. Pfizer’s SUN 1087 …
NICE responds to Daily Mail cancer drug claims
April 12, 2010Sales and Marketing NICE, Sutent, election, off label
NICE has responded to a Daily Mail article on access to cancer drugs, in order to clear up claims of …
Pfizer suffers late-stage cancer drug failures
March 12, 2010Research and Development Cancer, Pfizer, Sutent, figitumumab
Pfizer has suffered late-stage trial failures for Sutent and lung cancer candidate figitumumab. Kidney cancer drug Sutent (sunitinib) failed to …
Latest content
